PharmAust (ASX: PAA) chief executive officer Michael Thurn joins Small Caps to discuss his appointment to the company and recent trial developments.

The company recently released interim analysis of data from a Phase 1 clinical trial of its lead drug candidate monepantel (MPL) to treat motor neurone disease/amyotrophic lateral sclerosis (MND/ALS).

Results from an interim analysis of the trial indicated that neurofilament light chain (Nfl) protein concentrations in the plasma of participants in its Phase 1 clinical trial do not increase following MPL treatment – a positive sign.

PharmAust hopes that MPL could eventually receive orphan drug designation by the Therapeutics Goods Administration (TGA) and US Food and Drug Administration (FDA) for motor neurone disease, which affects over 350,000 people globally and kills more than 100,000 people yearly.

Article:
https://smallcaps.com.au/pharmaust-names-highly-experienced-biotech-specialist-chief-executive-officer/
https://smallcaps.com.au/pharmaust-interim-phase-1-data-mpl-inhibit-motor-neurone-disease/

For more information on PharmAust:
https://smallcaps.com.au/stocks/asx-paa/ 

See omnystudio.com/listener for privacy information.